APLT News and Press, Applied Therapeutics Inc. From 02/16/23

The ongoing Phase 3 INSPIRE trial is evaluating the effect of AT-007 vs. placebo in patients with SORD Deficiency on sorbitol reduction as well as clinical outcomes in approximately 50 patients age 16-55 in the US and Europe AT-007 reduced sorbitol by a mean of 52%, or approximately 16,00...

NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present virt...

Best Penny Stocks To Buy? 7 To Watch With Big Headlines In January 2023 Are you ready to get the ball rolling with penny stocks in 2023? You’re not alone, but unlike other years, chances are we’ll see much more volatility in the stock market. Heightened concerns over inflation, ...

Applied Therapeutics ( NASDAQ: APLT ) added ~19% pre-market Wednesday after announcing a partnership with U.K.-based pharmaceutical company Advanz Pharma to commercialize its lead candidate AT-007 (govorestat) in Europe. Per the terms, Advanz Pharma will receive the exclusive comm...

Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency Applied Therapeutics will receive milestone payments of over €130 million and 20% royalty payments on net s...

Applied Therapeutics press release ( NASDAQ: APLT ): Q3 GAAP EPS of -$0.40 beats by $0.12 . Cash and cash equivalents and short-term investments totaled $47.4 million as of September 30, 2022, compared with $80.8 million at December 31, 2021. For further details ...

NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today...

Additional preclinical data supports AT-001 as an effective treatment for Diabetic Cardiomyopathy, reducing cardiac fibrosis and adverse remodeling Baseline analysis of Phase 3 ARISE-HF study supports the primary endpoint (cardiac functional capacity as measured by Peak VO2) as ...

ARISE-HF is a global registrational study in 675 patients with Diabetic Cardiomyopathy (DbCM), evaluating the potential of AT-001 to improve or prevent worsening of cardiac function vs. placebo Primary study endpoint is cardiac functional capacity (measured by Peak VO 2 ...

Are These Penny Stocks To Buy Right Now Or Avoid Entirely? If you’re looking for penny stocks to buy right now, this article discusses three companies that Wall Street analysts have hefty expectations for. While these are some of the most volatile types of companies to trade,...